Clinical trials
Cardiotoxicity clinical trials
Below are recruiting cardiotoxicity clinical trials, each written for real people, not researchers. We’re tracking 51 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07528586Recruiting
Heart Imaging Study During Cancer Drug Treatment
This study uses heart imaging scans and blood tests to check if a common cancer drug (anthracycline) is affecting your heart during treatment. Early detection might help doctors protect your heart health.
StuttgartAges 18 years+ - NCT06340516Recruiting
Looking at a blood test to track heart health during HER2 breast cancer treatment
This trial is checking if a simple blood test (NT-proBNP) can help spot early signs of heart side effects from certain breast cancer treatments (chemotherapy plus HER2 blockers). If successful, it might help doctors adjust treatment sooner to protect your heart.
GothenburgAges 18 years+ - NCT07761910RecruitingPhase 2
Study of heart effects of radiation therapy using PET-CT for stage III lung cancer
This study looks at whether PET-CT scans can help detect heart damage caused by radiation therapy in patients with stage III lung cancer. If you're getting chemotherapy and radiation together, you may participate to help doctors find ways to reduce heart risks.
Indianapolis, IndianaAges 18 years+ - NCT07663357Recruiting
Blood test to detect heart damage from breast cancer treatment
This study looks at whether a simple blood test can spot early signs of heart damage from certain breast cancer treatments (anthracycline chemo or anti-HER2 drugs). The goal is to protect your heart while you get the cancer treatment you need.
Fortaleza, CearáAges 18 years+ - NCT04262830Recruiting
Heart scans to predict future heart failure after chemotherapy
This trial uses detailed heart imaging (a special MRI scan) to see how chemotherapy may have affected your heart and to predict who could develop heart failure later. If you qualify, it may help your care team better monitor your heart health over time.
San Diego, CaliforniaAges 13–39 - NCT06853951RecruitingPhase 3
Protecting hearts during chemotherapy in children
This trial tests whether a medication can prevent heart damage in children and teens receiving chemotherapy. It is for patients aged 2 to 18 who can take oral medication.
CairoAges 1–18 - NCT05465031RecruitingPhase 4
Testing heart-protection medicine during breast cancer treatment
This trial tests sacubitril/valsartan to help prevent heart weakness (cardiotoxicity) caused by breast cancer treatments like anthracyclines and/or anti-HER2 drugs. If you qualify, you may be offered this heart-protection medicine while your cancer is treated.
Opole, Opole VoivodeshipAges 18 years+ - NCT07191730Recruiting
Heart risk prediction for cancer patients on certain chemotherapies
This trial uses a special scoring system (ML Score) to predict if you might develop heart problems while receiving anthracycline chemotherapy or HER2-targeted therapies. It helps doctors decide on the best heart monitoring plan before starting treatment.
CaenAges 18 years+ - NCT06132984Recruiting
Heart MRI monitoring for immunotherapy-related heart issues
This study uses heart MRIs to monitor women with gynecologic cancers who are about to start immunotherapy. The goal is to detect early signs of heart problems so doctors can take action quickly.
Chengdu, SichuanAges 18–75 - NCT04822077Recruiting
Proton beam treatment for thymus tumors
This trial studies proton radiotherapy (a type of radiation) for cancers of the thymus, like thymoma or thymic carcinoma. It may help improve tumor control while limiting radiation exposure to nearby organs.
Umeå, NorrlandAges 18 years+ - NCT05732051RecruitingPhase 2
Nicotinamide riboside to protect the heart during breast cancer chemo
This trial tests whether nicotinamide riboside can help prevent heart problems caused by a common breast-cancer chemotherapy (anthracyclines). If you’re eligible, you’ll be followed to see how your heart is doing during treatment.
Lørenskog, AkershusAges 18 years+ - NCT06214195RecruitingPhase 3
Shengmai San to prevent heart damage from breast cancer therapy
This trial tests if a traditional Chinese medicine called Shengmai San can protect the heart during chemotherapy and targeted therapy for HER2-positive breast cancer. Patients take the supplement alongside standard treatment to see if it reduces the risk of heart problems.
Hangzhou, ZhejiangAges 18 years+ - NCT06282796Recruiting
Early heart risk monitoring for breast cancer chemo
This study tests a method to predict and warn about heart damage from a common type of breast cancer chemotherapy. If you have HER2-positive breast cancer and will receive anthracycline drugs, this trial may help monitor your heart health.
Fuzhou, FujianAges 18–80 - NCT06270667Recruiting
Exercise training for lymphoma survivors
This study tests whether a supervised exercise program can improve heart health in people who finished treatment for Hodgkin or aggressive non-Hodgkin lymphoma 2–5 years ago. The goal is to see if regular exercise helps your heart recover better after chemotherapy or chest radiation.
OsloAges 20–70 - NCT05851053Recruiting
Study of heart function years after breast cancer treatment
This study checks how well your heart works long after breast cancer treatment. If you joined the earlier de BLOC-I study, you may be invited for follow-up to understand long-term heart effects.
GroningenAges Any age - NCT05769868RecruitingPhase 3
Esmolol test to spot heart problems in diabetes, cirrhosis, and cancer
This trial tests whether esmolol (a short-acting heart medicine) can help doctors identify certain heart-related problems in people with type 2 diabetes, liver scarring (cirrhosis), or specific cancers. It’s mainly about improving how heart issues are detected during ultrasound testing.
Barcelona, BarcelonaAges 18 years+ - NCT05703126Recruiting
Blood vessel and heart strength tests in AML patients
This study looks at how well your blood vessels and heart pumping ability work in people with acute myeloid leukemia (AML) receiving certain chemotherapy. It may help doctors better understand heart risk during treatment and tailor monitoring to you.
Samara, Samara OblastAges 18–65 - NCT07654426RecruitingPhase 2
Heart protection during lymphoma chemotherapy
This trial tests if a heart-protecting drug (dexrazoxane) can prevent heart damage in people getting chemotherapy for certain types of large B-cell lymphoma. It is for patients who already have heart risk factors or a history of heart failure.
Boston, MassachusettsAges 18 years+ - NCT07588425Recruiting
Monitoring heart health during breast cancer treatment
This study watches how chemotherapy and HER2-targeted drugs affect your heart during early-stage breast cancer treatment. Researchers use heart scans to catch any changes early and understand how to protect heart health.
Ankara, AnkaraAges 18 years+ - NCT06774326Recruiting
Spectral CT to check for heart damage from lymphoma treatment
This study uses a special type of CT scan called spectral CT to see if chemotherapy drugs called anthracyclines can cause heart damage in people with certain lymphomas. The goal is to catch any heart problems early by imaging the heart before, during, and after treatment.
BolognaAges 18 years+ - NCT07426913Recruiting
Virtual reality heart health for breast cancer survivors
This trial tests if a virtual reality program can help breast cancer survivors taking certain chemotherapies improve their heart health. It's for people currently receiving trastuzumab or anthracycline-based treatment, along with immunotherapy, for their first breast cancer diagnosis.
Richmond, VirginiaAges 18 years+ - NCT07382141Recruiting
Heart Health Monitoring During Childhood Cancer Treatment
This study looks at how chemotherapy and other cancer treatments affect the heart in children. It aims to find heart problems early so they can be treated quickly.
Bologna, BolognaAges birth–18 years - NCT06664528Recruiting
Heart health study for adults getting certain chemo
This study tracks the heart health of adults receiving chemotherapy that may affect the heart. It helps doctors understand how to better monitor and protect patients.
Rome, LazioAges 18 years+ - NCT03711110Recruiting
Heart-protection plan for older people with certain cancers
This trial looks at strategies to help prevent heart and blood-vessel problems in people over 65 who have certain cancers. It may help by monitoring and treating heart risks early to lower the chance of future cardiovascular events.
Santiago de Compostela, A CoruñaAges 65 years+
Hear when a new Cardiotoxicity trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Cardiotoxicity trials by city
Studies with a site in or near these metro areas.
Cardiotoxicity trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for cardiotoxicity?
- Yes. Clin2 currently lists 51 recruiting cardiotoxicity studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a cardiotoxicity trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a cardiotoxicity trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.